Clover Health Investments, Corp. (CLOV)
| Market Cap | 2.64B +91.3% |
| Revenue (ttm) | 2.74B +54.5% |
| Net Income | 12.45M |
| EPS | 0.02 |
| Shares Out | 535.42M |
| PE Ratio | 252.82 |
| Forward PE | 61.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,781,866 |
| Open | 4.820 |
| Previous Close | 4.830 |
| Day's Range | 4.700 - 4.930 |
| 52-Week Range | 1.580 - 5.590 |
| Beta | 2.48 |
| Analysts | Buy |
| Price Target | 5.60 (+13.59%) |
| Earnings Date | Nov 4, 2026 |
About CLOV
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Financial Performance
In 2025, Clover Health Investments's revenue was $1.92 billion, an increase of 40.33% compared to the previous year's $1.37 billion. Losses were -$85.55 million, 98.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CLOV stock is "Buy." The 12-month stock price target is $5.6, which is an increase of 13.59% from the latest price.
News
Clover Health Investments Transcript: UBS Global Healthcare Conference
YTD 2026 adjusted EBITDA reached $97 million and net income $62 million, with membership growth of ~50% and medical trends favorable to expectations. Strong 2027 growth is supported by competitive PPO positioning, cohort maturation, and a New Jersey plan exit affecting ~40,000 MA members.
Clover Health price target raised to $5.50 from $5 at UBS
UBS raised the firm’s price target on Clover Health (CLOV) to $5.50 from $5 and keeps a Neutral rating on the shares.
Clover Health Investments Earnings Call Transcript: Q3 2026
9M growth and improving profitability support expected first full-year GAAP net income profitability in 2026. Five-Star PPO ratings, maturing cohorts, and operating leverage underpin the 2027–2028 earnings opportunity, while FY26 guidance was raised at the low end.
Clover Health Investments Earnings release: Q3 2026
Clover Health Investments released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Clover Health Investments Slides: Q3 2026
Clover Health Investments has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Clover Health Investments Quarterly report: Q3 2026
Clover Health Investments has published its Q3 2026 quarterly earnings report on November 4, 2026.
Clover Health Reports Third Quarter 2026 Results
Business Highlights: Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth Improved Full Year 2026 guida...
Clover Health initiated with a Buy at Needham
Needham initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target The firm sees a “compelling” long-term earnings opportunity as the Clover Assistant enabled care model…
Clover Health to Participate in Upcoming UBS Global Healthcare Conference
WILMINGTON, Del., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Offic...
Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States
WILMINGTON, Del., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health” or “Clover”), a physician enablement technology company committed to bringing acces...
Clover Health Medicare Advantage PPO plans earn 5 star rating for 2027
Clover Health (CLOV) Investments announced that the Centers for Medicare & Medicaid Services has awarded its PPO Medicare Advantage plans a rating of 5 Stars and its HMO MA plan…
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medica...
Clover Health up over 8% after-hours following CMS Star Ratings update
Shares of Clover Health (CLOV) are up 8.5% after-hours at $4.97 after the release of 2027 Medicare Advantage and Part D Star Ratings that boosted Clover’s rating to 5 stars…
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial res...
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to...
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senato...
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senato...
Clover Health Investments Transcript: 2026 Jefferies Healthcare Services and Technology Conference
A differentiated technology-driven approach, full-risk model, and focus on PPO plans underpin strong member retention and growth. Industry-wide pricing discipline and benefit stability are driving selective disruption, while ongoing AI and R&D investments support margin recovery and profitability.
Clover Health initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target The firm views Clover as an investment in the expanding Medicare Advantage market at…
Clover Health initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following inv...
Clover Health Investments Transcript: Canaccord Genuity's 46th Annual Growth Conference
The presentation highlighted a differentiated, technology-driven approach to Medicare Advantage, emphasizing proactive care, rapid membership growth, and strong retention. Cohort maturation and in-home care are driving profitability, with expectations for continued expansion and industry-leading outcomes.
Clover Health Investments Slides: Investor presentation
Clover Health Investments has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.